Please login to the form below

Not currently logged in
Email:
Password:

Positive results for oral MS treatments

Three separate studies have shown oral drugs for multiple sclerosis (MS) - cladribine and fingolimod - to be at least as effective as current treatments

Three separate studies have shown oral drugs for multiple sclerosis (MS), cladribine and fingolimod, to be at least as effective as current treatments.

The studies, published in the New England Journal of Medicine, each involved over 1,000 patients from over 18 countries as part of three phase III clinical trials, two involving fingolimod and one involving cladribine.

If successful these would be the first oral treatments available for the neurological disorder.

Results for the studies, which tested the effectiveness and safety of the drugs for relapsing remitting MS, saw relapse rates cut by 50-60 per cent over two years compared with placebos for both drugs.

Fingolimod was also tested against widely-used injection, beta-interferon-1a, with the proposed drug reducing relapse rates by 52 per cent compared with the standard treatment. Brain lesion activity was also found to be reduced, though no effect on disability progression was observed in the trial. 

Dr Doug Brown, biomedical research manager at the MS Society, said: "This is great news for people with MS and signifies a shifting tide in the treatment of the condition. Availability of oral therapies will give people greater choice and being able to take a tablet instead of unpleasant injections will come as welcome relief. The evidence is now there and we will be working with the relevant authorities to make sure those who will benefit can get access."

Merck Serono, the makers of cladribine, applied for a license to market the pill in the UK in July 2009 while Novartis, the makers of fingolimod, applied for a license to market their drug in the UK in December 2009

Both are currently awaiting a decision by the regulatory authorities.

If the decision is positive, both drugs could be available as early as 2011.

21st January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics